Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) will host a live audio webcast at the Goldman Sachs 35th Annual Global Healthcare Conference. Eyal Desheh, EVP & CFO will present on Tuesday, June 10, 2014 at 2 PM PT. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) net profit margin is 6.80% and weekly performance is 1.17%. On last trading day company shares ended up $51.08. Analysts mean target price for the company is $ 55.91. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) distance from 50-day simple moving average (SMA50) is 1.34%.
GlaxoSmithKline plc (ADR) (NYSE:GSK) announced that it has initiated a phase III study, LATITUDE-TIMI 60 on cardiovascular candidate losmapimod. Glaxo is evaluating the efficacy of losmapimod in patients suffering from acute coronary syndrome. GlaxoSmithKline plc (ADR) (NYSE:GSK) shares advanced 0.75% in last trading session and ended the day on $53.70. GSK Gross Margin is 69.60% and its return on assets is 17.30%. GlaxoSmithKline plc (ADR) (NYSE:GSK) quarterly performance is -2.17%.
On June 5, 2014, Mylan Inc (NASDAQ:MYL) announced that the company will present at the Goldman Sachs 35th Annual Global HealthCare Conference on Tuesday, June 10, 2014, in Rancho Palos Verdes. The presentation is scheduled to begin at 8:40 a.m. PT. Mylan Inc (NASDAQ:MYL) shares moved down -0.22% in last trading session and was closed at $49.73, while trading in range of $49.37 – $50.09. Mylan Inc (NASDAQ:MYL) year to date (YTD) performance is 14.59%.
On June 2, Sanofi SA (ADR) (NYSE:SNY) resubmitted supplemental Biologics License Application (sBLA) for Lemtrada (alemtuzumab) has been accepted by the U.S. Food and Drug Administration (:FDA) for review. The company is looking to get Lemtrada approved for the treatment of relapsing forms of multiple sclerosis. Sanofi SA (ADR) (NYSE:SNY) ended the last trading day at $54.10. Company weekly volatility is calculated as 0.61% and price to cash ratio as 24.91. Sanofi SA (ADR) (NYSE:SNY) showed a positive weekly performance of 1.50%.
On June 5, Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) Ventana Medical Systems, Inc. has entered into a collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Both the companies are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune’s MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma. The deal includes the MEDI4736 ATLANTIC trial that will enroll only patients who express PD-L1 as determined by the VENTANA assay. Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY)shares closed at $37.58 in last trading session, while 52 week range of $28.61 – $38.71.
Leave a Reply